Squadron Capital Management as of June 30, 2026
Portfolio Holdings for Squadron Capital Management
Squadron Capital Management holds 38 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Relmada Therapeutics (RLMD) | 15.8 | $51M | 7.4M | 6.92 | |
| C4 Therapeutics Com Stk (CCCC) | 11.0 | $36M | 7.6M | 4.67 | |
| Cogent Biosciences (COGT) | 10.4 | $34M | 865k | 38.70 | |
| Zentalis Pharmaceuticals Call Option (ZNTL) | 6.2 | $20M | 4.1M | 4.85 | |
| Kodiak Sciences (KOD) | 6.0 | $20M | 500k | 38.96 | |
| Relay Therapeutics (RLAY) | 5.6 | $18M | 970k | 18.71 | |
| Edgewise Therapeutics (EWTX) | 3.7 | $12M | 290k | 40.63 | |
| Maze Therapeatics (MAZE) | 3.1 | $10M | 335k | 29.84 | |
| Bioage Labs Call Option (BIOA) | 3.1 | $9.9M | 405k | 24.51 | |
| Inventiva Sa Ads (IVA) | 2.9 | $9.2M | 2.4M | 3.78 | |
| Adlai Nortye Sponsored Ads (ANL) | 2.7 | $8.8M | 765k | 11.50 | |
| Compass Pathways Sponsored Ads (CMPS) | 2.7 | $8.6M | 605k | 14.15 | |
| Enliven Therapeutics (ELVN) | 2.5 | $8.1M | 160k | 50.75 | |
| Rezolute Com New (RZLT) | 2.1 | $6.8M | 1.3M | 5.20 | |
| Arrivent Biopharma Call Option (AVBP) | 2.0 | $6.4M | 183k | 34.74 | |
| Palisade Bio (PALI) | 1.9 | $6.3M | 3.0M | 2.09 | |
| Inhibikase Therapeutics Com New (IKT) | 1.9 | $6.1M | 3.0M | 2.03 | |
| Adagene Ads (ADAG) | 1.6 | $5.3M | 1.3M | 4.20 | |
| Forte Biosciences Com New (FBRX) | 1.5 | $4.8M | 225k | 21.25 | |
| Inflarx Nv (IFRX) | 1.4 | $4.5M | 2.0M | 2.24 | |
| Assembly Biosciences Com New (ASMB) | 1.4 | $4.4M | 160k | 27.48 | |
| Promis Neurosciences Com Shs (PMN) | 1.3 | $4.3M | 325k | 13.16 | |
| Contineum Therapeutics Cl A (CTNM) | 1.3 | $4.3M | 260k | 16.39 | |
| Definium Therapeutics Com Shs (DFTX) | 1.2 | $4.0M | 85k | 47.04 | |
| Sol-gel Technologies Shs New (SLGL) | 1.2 | $3.9M | 52k | 74.14 | |
| Scynexis | 1.0 | $3.1M | 757k | 4.07 | |
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.9 | $2.8M | 1.5M | 1.86 | |
| Disc Medicine Call Option (IRON) | 0.7 | $2.2M | 30k | 73.14 | |
| Lipocine Com New (LPCN) | 0.6 | $2.1M | 810k | 2.56 | |
| Ultragenyx Pharmaceutical Call Option (RARE) | 0.6 | $1.8M | 55k | 33.39 | |
| Cue Biopharma (CUE) | 0.5 | $1.6M | 50k | 31.56 | |
| Calcimedica Com New (CALC) | 0.4 | $1.3M | 1.2M | 1.03 | |
| Quince Therapeutics | 0.2 | $734k | 40k | 18.19 | |
| Nuvectis Pharma Call Option (NVCT) | 0.2 | $712k | 39k | 18.39 | |
| Pasithea Therapeutics Corp Com New (KTTA) | 0.2 | $515k | 1.0M | 0.52 | |
| Inmed Pharmaceuticals Com New (INM) | 0.2 | $504k | 325k | 1.55 | |
| Neumora Therapeutics (NMRA) | 0.1 | $170k | 100k | 1.70 | |
| Nextcure Com New (NXTC) | 0.0 | $103k | 65k | 1.60 |
